Pharmaceutical Executive-12-01-2021

For biopharma innovation to succeed and accelerate, companies must stop duplicating their efforts and share valuable information.

Chief commercial officers gather for an insightful roundtable discussion anchored in the future of sales and marketing in light of new communication media brought on by the pandemic.

Our annual report takes a look at pharma’s current investment in drug development, which this year demonstrates a focus on five important therapeutic areas of interest—Alzheimer’s disease, ophthalmology, NASH, anti-infectives, and opioids.

After two decades at the forefront of hematology and oncology drug development, AbbVie’s vice president and global head of oncology clinical development, Mohamed Zaki, MD, PhD, is more hopeful than ever about recent advances in the space.

Industry growth in innovation could spark financial rebound.

Potential for quality equivalent to economies of scale.

Critics proclaim that recent RWD guidance issued by FDA still has a good number of gaps to fill and may take some time to accomplish.

It’s time to see how you’re doing with putting words into action.

Lack of IP management plagues recent regulatory discussions.

COVID vaccine development highlights need for modernization.

Looking Back at 2018–2021.

COVID pandemic brings increased attention to other infectious diseases.

Click the title above for a link to open the Pharmaceutical Executive December 2021 issue in an interactive PDF format.